Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
about
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.Severe Hypernatraemic Dehydration and Unconsciousness in a Care-Dependent Inpatient Treated with Empagliflozin.Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes.Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors: Protocol for a systematic review and meta-analysis
P2860
Q36316732-8FE767D6-C374-4836-A5E6-27F8C7FC85D7Q38940175-AD04FA24-A2C7-4C09-B845-4F4D459E31CDQ39000587-FAB0B951-42BB-4E10-9880-8F32DEB4E1C0Q39170860-E8492777-9995-4792-8079-7490951188E6Q39255188-DA1F3022-244F-4EA2-9ABC-DF7DACE851D2Q40405896-A8CED51B-6B7A-409F-BB1F-4BCBEB9F7B85Q47105157-010BA09A-2797-424B-AD12-90CA2EC2B67EQ47918474-83AF6DB7-0E9B-455B-A10D-F34CDD559948Q52587186-ED385053-8F0C-462C-9F5F-BE484D95AAF8Q58789064-05ED9546-1EBD-4B01-9858-B87E0F640B43
P2860
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Osmotic diuresis with SGLT2 in ...... dapagliflozin clinical trials.
@ast
Osmotic diuresis with SGLT2 in ...... dapagliflozin clinical trials.
@en
type
label
Osmotic diuresis with SGLT2 in ...... dapagliflozin clinical trials.
@ast
Osmotic diuresis with SGLT2 in ...... dapagliflozin clinical trials.
@en
prefLabel
Osmotic diuresis with SGLT2 in ...... dapagliflozin clinical trials.
@ast
Osmotic diuresis with SGLT2 in ...... dapagliflozin clinical trials.
@en
P2093
P2860
P1476
Osmotic diuresis with SGLT2 in ...... dapagliflozin clinical trials.
@en
P2093
Agata Ptaszynska
Eva Johnsson
Kristina Johnsson
Shamik J Parikh
Traci A Mansfield
Yshai Yavin
P2860
P304
P356
10.1080/00325481.2016.1153941
P407
P577
2016-02-15T00:00:00Z